HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
PGNY
Progyny, Inc.
PGNY's fundamentals are strong and it looks cheap: trading at 34x earnings, below its usual 43x. Analysts expect strong earnings growth.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
PGNY Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Strong |
PGNY's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
PGNY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 24x | $36.58 | — |
| Cheap | 32x | $34.56 | -5.5% |
| Current | 34x | $36.58 | — |
| Fair | 43x | $46.46 | +27% |
| Expensive | 91x | $98.79 | +170% |
Historical ranges are pointers, not guarantees.
PGNY's PE is in its cheap range at 34x. If earnings grow as analysts expect, today's price would be 24x next year's earnings.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
PGNY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
PGNY has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
PGNY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.54 | +41% |
| Q3 2026 | $1.09 | +73% |
| Q2 2026 | $0.92 | +56% |
| Q1 2026 | $0.77 | +35% |
| Q4 2025 | $0.65 | +14% |
| Q3 2025 | $0.63 | +8.6% |
| Q2 2025 | $0.59 | -6.3% |
| Q1 2023 | $0.43 | -23% |
| Q4 2022 | $0.30 | -55% |
PGNY has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over PGNY on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
PGNY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $341.3M | +8.9% |
| Q2 2026 | $350.5M | +5.3% |
| Q1 2026 | $328.5M | +1.4% |
| Q4 2025 | $318.4M | +6.7% |
| Q3 2025 | $313.3M | +9.3% |
| Q2 2025 | $332.9M | +9.5% |
| Q1 2025 | $324M | +17% |
| Q4 2024 | $298.4M | +11% |
PGNY's revenue has grown year over year every quarter since late 2020: $341M last quarter, up 8.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 10% | +3.4 points |
| Q2 2026 | 11% | +4.1 points |
| Q1 2026 | 11% | +3.3 points |
| Q4 2025 | 4.8% | -0.5 points |
| Q3 2025 | 6.9% | +2.5 points |
| Q2 2025 | 7.3% | +0.5 points |
| Q1 2025 | 7.5% | +0.8 points |
| Q4 2024 | 5.3% | +0.2 points |
PGNY has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over PGNY on cash flow, with more consistent year-over-year improvement.
PGNY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $47.2M | +2.7% |
| Q2 2026 | $44.2M | -12% |
| Q1 2026 | $39.6M | -16% |
| Q4 2025 | $48.6M | -3.3% |
| Q3 2025 | $46M | +7.6% |
| Q2 2025 | $50.2M | -10% |
| Q1 2025 | $47M | +89% |
| Q4 2024 | $50.3M | +36% |
PGNY generated $180M in free cash flow over the past year, down 7.1% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has 234M diluted shares, down 6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
PGNY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.2% | -969K shares |
| 1 year | -10% | -9.1M shares |
| 3 years | -20% | -19.7M shares |
| 5 years | -19% | -19.2M shares |
| Available history | +26% | +17M shares |
PGNY has the edge over HIMS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $82.8M |
| Q2 2026 | $30M |
| Q1 2026 | $118.6M |
| Q4 2025 | $81.7M |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $55.1M |
PGNY spent $313M buying back its own shares over the past year, about six times what it spent the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
PGNY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.9x | Net Cash |
| Q2 2026 | -1.3x | Net Cash |
| Q1 2026 | -1.3x | Net Cash |
| Q4 2025 | -1.2x | Net Cash |
| Q3 2025 | -1.5x | Net Cash |
| Q2 2025 | -1.6x | Net Cash |
| Q1 2025 | -1.4x | Net Cash |
| Q4 2024 | -2.3x | Net Cash |
PGNY has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
PGNY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 73.2 | Overbought |
| Stochastic | 84.8 | Overbought |
PGNY's weekly RSI is 73 (overbought) and its Stochastic is 85 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
PGNY PE vs Healthcare Sector
| Metric | PGNY | Sector median | Relative |
|---|---|---|---|
| PE | 34x | 26x | 30% above |
| PE % | 21 | 29 | 8 pts below |
PGNY is trading at 34x earnings, a 30% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
PGNY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.4 | 25% above |
| 20 week MA | $28.8 | 27% above |
| 50 week MA | $25.0 | 46% above |
| 100 week MA | $23.3 | 57% above |
| 200 week MA | $27.3 | 34% above |
PGNY has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
PGNY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $28.0 | $42.2 | +51% |
| 2021 | $42.2 | $51.5 | +22% |
| 2022 | $51.5 | $30.8 | -40% |
| 2023 | $30.8 | $37.2 | +21% |
| 2024 | $37.2 | $16.9 | -55% |
| 2025 | $16.9 | $25.8 | +53% |
| 2026 YTD | $25.8 | $36.6 | +42% |
PGNY has the edge over HIMS on returns for 2026, with the stronger performance.